ANTIPSYCHOTIC TREATMENT EMERGENT ADVERSE EVENTS IN
CORRELATION WITH THE PHARMACOGENETIC TESTING AND
DRUG INTERACTIONS IN CHILDREN AND ADOLESCENTS WITH
SCHIZOPHRENIA AND BIPOLAR DISORDER
NICOLETA ANDREESCU1#, LAURA NUSSBAUM2 #*, LAVINIA MARIA HOGEA3#, RALUCA GRĂDINARU1, CĂLIN MUNTEAN4#, RADU ȘTEFĂNESCU5, MARIA PUIU1
1Genetics Discipline, Microscopic Morphology Department, University of Medicine and Pharmacy “Victor Babeș”, no. 2, E.
Murgu Square Timișoara, Romania
2Pedopsychiatry Discipline, Department of Neurosciences, University of Medicine and Pharmacy “Victor Babeș”, no. 2, E.
Murgu Square, Timișoara, Romania
3Psychology Discipline, Department of Neurosciences, University of Medicine and Pharmacy “Victor Babeș”, no. 14, T.
Vladimirescu Street, Timișoara, Romania
4 Discipline of Informatics and Medical Biostatistics, Department of Functional Sciences, University of Medicine and Pharmacy
“Victor Babeș”, no. 14, T. Vladimirescu Street, Timișoara, Romania
5Titu Maiorescu University, School of Medicine, Bucharest, Romania
*corresponding author: nussbaumlaura@yahoo.com
#These authors contributed equally to this work.
Download Full Article

Abstract:
Even though a shift toward the use of second generation of modern atypical antipsychotics was partly justified by their lower risk
of extrapyramidal symptoms, their serious adverse effects include high risk of weight gain, hyperinsulinemia, metabolic syndrome,
type 2 diabetes mellitus. Especially in children and adolescents, the choice of antipsychotic medication should be driven by the
safety and side effects profiles. The present study is part of an extensive research on pharmacological treatment in child and
adolescent psychoses, performed between 2007 and 2015, focused especially on safety aspects, treatment emergent adverse
events (TEAE) and pharmacogenetic correlations. The study group consisted of 90 patients, children and adolescents with
psychosis (schizophrenia and bipolar disorder). The primary objective of our study was to evaluate the safety and the adverse
events of aripiprazole compared with risperidone in the studied paediatric population. Also a major objective was to establish
some correlations between the pharmacogenetic profile of the subjects and the presence of treatment emergent adverse
events. We investigated also variables like BMI (Body Mass Index), blood insulin increase in different time points after the
long duration administration of the antipsychotic treatment. The obtained results proved a high safety profile, especially for
aripiprazole and high correlations of the emergence of the adverse events with the pharmacogenetic profile of the subjects.

Top